56 studies found for:    regorafenib
Show Display Options
Rank Status Study
1 Recruiting Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Cetuximab (ERBITUX)
2 Recruiting Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Condition: Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
3 Active, not recruiting Effect of Neomycin on the Pharmacokinetics of Regorafenib
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Neomycin
4 Recruiting Regorafenib Post-marketing Surveillance
Condition: Colorectal Neoplasms
Intervention: Drug: BAY73-4506_Regorafenib
5 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
6 Recruiting Regorafenib and Cetuximab in Patients With Advanced Malignancy
Condition: Advanced Cancers
Interventions: Drug: Regorafenib;   Drug: Cetuximab;   Behavioral: Questionnaire
7 Not yet recruiting Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: PF-03446962;   Drug: Regorafenib
8 Recruiting Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Condition: Cancer of the Bile Duct
Intervention: Drug: Regorafenib
9 Completed Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
Condition: Pharmacokinetics
Intervention: Drug: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
10 Recruiting Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506);   Drug: FOLFIRI;   Drug: Placebo
11 Recruiting Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Regorafenib
12 Not yet recruiting Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Condition: Neoplasms
Interventions: Drug: Digoxin;   Drug: Rosuvastatin;   Drug: Regorafenib (Stivarga, BAY73-4506)
13 Recruiting Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
Condition: Advanced Chemorefractory Colorectal Adenocarcinoma
Intervention: Drug: regorafenib
14 Terminated Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed;   Drug: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
15 Completed The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib
Conditions: Dietary Fats;   Pharmacokinetics
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
16 Recruiting Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73- 4506)
17 Completed Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Condition: Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
18 Recruiting FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Interventions: Drug: Regorafenib;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin
19 Recruiting Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Conditions: Adult Angiosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Intervention: Drug: regorafenib
20 Active, not recruiting
Has Results
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Oxaliplatin;   Drug: Folinic acid;   Drug: 5-FU (mFOLFOX6)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years